Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25–69 years living in Australia-Reference-Cited by-同舟云学术

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25–69 years living in Australia

Published:2018-01 Issue:1 Volume:8 Page:e016700
ISSN:2044-6055
Container-title:BMJ Open
language:en
Short-container-title:BMJ Open

Author:

Canfell Karen,Saville Marion,Caruana Michael,Gebski Val,Darlington-Brown Jessica,Brotherton Julia,Heley Stella,Castle Philip E

Funder

Victorian Cytology Service Ltd

Roche Molecular Systems and Ventana Inc USA

Cancer Council New South Wales

Publisher

BMJ

Subject

General Medicine

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlates of intention-to-attend and confirmed cervical screening attendance during the COVID-19 pandemic in Australia: Findings from Compass-PLUS, a prospective cohort study;Preventive Medicine Reports;2024-09

2. Effectiveness of high-risk human papillomavirus genotyping for cervical cancer screening. A multicentre screening cohort study in rural China;Anales del Sistema Sanitario de Navarra;2024-05-31

3. Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study;Cancer Epidemiology, Biomarkers & Prevention;2024-05-22

4. Evaluation of p16/Ki‐67 dual‐stain as triage test for high‐risk HPV ‐positive women: A hospital‐based cross‐sectional study;Cancer Cytopathology;2022-07-19

5. Clinical Performance of Triage Strategies for Hr-HPV–Positive Women; A Longitudinal Evaluation of Cytology, p16/K-67 Dual Stain Cytology, and HPV16/18 Genotyping;Cancer Epidemiology, Biomarkers & Prevention;2022-05-05